Targeting efflux pumps to overcome antifungal drug resistance

Future Medicinal Chemistry

Volumn 8, Issue 12, 2016, Pages 1485-1501

  Holmes, Ann R ^a   Cardno, Tony S ^b,c,d   Strouse, J Jacob ^e   Ivnitski Steele, Irena ^e   Keniya, Mikhail V ^a   Lackovic, Kurt ^c,d   Monk, Brian C ^a   Sklar, Larry A ^e   Cannon, Richard D ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

ABC and MFS transporters; antifungal drug resistance; azole; chemosensitization; heterologous expression; high throughput screen

Indexed keywords

ABC TRANSPORTER; ANTIFUNGAL AGENT; FLUORESCENT DYE; FUNGAL EFFLUX PUMP PROTEIN; FUNGAL PROTEIN; PYRROLE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT; CARRIER PROTEIN; PYRROLE DERIVATIVE;

ANTIFUNGAL RESISTANCE; CHEMOSENSITIZATION; GROWTH INHIBITION; HETEROLOGOUS EXPRESSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES CEREVISIAE; CHEMISTRY; DRUG EFFECTS; FUNGUS; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MYCOSES; SYNTHESIS;

ANTIFUNGAL AGENTS; AZOLES; DRUG RESISTANCE, FUNGAL; FUNGI; HUMANS; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; MYCOSES;

EID: 84982124893     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc-2016-0050     Document Type: Review

References (106)

1. Michael CA, Dominey-Howes D, Labbate M. The antimicrobial resistance crisis: causes, consequences, and management. Front. Public Health. 2, 145 (2014).
2. Prasad R, Shah AH, Rawal MK. Antifungals: mechanism of action and drug resistance. Adv. Exp. Med. Biol. 892, 327-349 (2016).
3. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. www.cdc.gov/drugresistance/threat-report-2013
4. Charlier C, El Sissy C, Bachelier-Bassi S et al. Acquired flucytosine resistance during combination therapy with caspofungin and flucytosine for Candida glabrata cystitis. Antimicrob. Agents Chemother. 60(1), 662-665 (2015).
5. Dodgson AR, Dodgson KJ, Pujol C, Pfaller MA, Soll DR. Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans. Antimicrob. Agents Chemother. 48(6), 2223-2227 (2004).
6. Hope WW, Tabernero L, Denning DW, Anderson MJ. Molecular mechanisms of primary resistance to flucytosine in Candida albicans. Antimicrob. Agents Chemother. 48(11), 4377-4386 (2004).
7. Mesa-Arango AC, Trevijano-Contador N, Roman E et al. The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug. Antimicrob. Agents Chemother. 58(11), 6627-6638 (2014).
8. Jensen RH, Astvad KM, Silva LV et al. Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in Candida albicans orchestrated by multiple genetic alterations. J. Antimicrob. Chemother. 70(9), 2551-2555 (2015).
9. Arendrup MC, Perlin DS. Echinocandin resistance: an emerging clinical problem? Curr. Opin. Infect. Dis. 27(6), 484-492 (2014).
10. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10(3), 121-130 (2007).
11. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazoleresistant bloodstream isolates of Candida glabrata. J. Clin. Microbiol. 50(4), 1199-1203 (2012).
12. Liu JY, Shi C, Wang Y, Li WJ, Zhao Y, Xiang MJ. Mechanisms of azole resistance in Candida albicans clinical isolates from Shanghai, China. Res. Microbiol. 166(3), 153-161 (2015).
13. Mane A, Vidhate P, Kusro C et al. Molecular mechanisms associated with fluconazole resistance in clinical Candida albicans isolates from India. Mycoses 59(2), 93-100 (2016).
14. Cannon RD, Lamping E, Holmes AR et al. Effluxmediated antifungal drug resistance. Clin. Microbiol. Rev. 22(2), 291-321 (2009).
15. Niimi K, Maki K, Ikeda F et al. Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility. Antimicrob. Agents Chemother. 50(4), 1148-1155 (2006).
16. Holmes AR, Lin YH, Niimi K et al. ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates. Antimicrob. Agents Chemother. 52(11), 3851-3862 (2008).
17. Tsao S, Rahkhoodaee F, Raymond M. Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance. Antimicrob. Agents Chemother. 53(4), 1344-1352 (2009).
18. Goldstein LJ, Galski H, Fojo A et al. Expression of a multidrug resistance gene in human cancers. J. Natl Cancer Inst. 81(2), 116-124 (1989).
19. Kathawala RJ, Gupta P, Ashby CR Jr., Chen ZS. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist. Updat. 18, 1-17 (2015).
20. Gottesman MM, Pastan IH. The role of multidrug resistance efflux pumps in cancer: revisiting a JNCI publication exploring expression of the MDR1 (P-glycoprotein) gene. J. Natl Cancer Inst. 107(9), djv222 (2015).
21. Lamping E, Baret PV, Holmes AR, Monk BC, Goffeau A, Cannon RD. Fungal PDR transporters: phylogeny, topology, motifs and function. Fungal Genet. Biol. 47(2), 127-142 (2010).
22. Aparna V, Dineshkumar K, Mohanalakshmi N, Velmurugan D, Hopper W. Identification of natural compound inhibitors for multidrug efflux pumps of Escherichia coli and Pseudomonas aeruginosa using in silico high-throughput virtual screening and in vitro validation. PLoS ONE 9(7), e101840 (2014).
23. Gupta S, Cohen KA, Winglee K, Maiga M, Diarra B, Bishai WR. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 58(1), 574-576 (2014).
24. Grossman TH, Shoen CM, Jones SM, Jones PL, Cynamon MH, Locher CP. The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents. Antimicrob. Agents Chemother. 59(3), 1534-1541 (2015).
25. Lomovskaya O, Zgurskaya HI, Totrov M, Watkins WJ. Waltzing transporters and 'the dance macabre' between humans and bacteria. Nat. Rev. Drug Discov. 6(1), 56-65 (2007).
26. Murakami S, Nakashima R, Yamashita E, Matsumoto T, Yamaguchi A. Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature 443(7108), 173-179 (2006).
27. Nakashima R, Sakurai K, Yamasaki S et al. Structural basis for the inhibition of bacterial multidrug exporters. Nature 500(7460), 102-106 (2013).
28. Nakashima R, Sakurai K, Yamasaki S, Nishino K, Yamaguchi A. Structures of the multidrug exporter AcrB reveal a proximal multisite drug-binding pocket. Nature 480(7378), 565-569 (2011).
29. Sennhauser G, Amstutz P, Briand C, Storchenegger O, Grutter MG. Drug export pathway of multidrug exporter AcrB revealed by DARPin inhibitors. PLoS Biol. 5(1), e7 (2007).
30. Sennhauser G, Bukowska MA, Briand C, Grutter MG. Crystal structure of the multidrug exporter MexB from Pseudomonas aeruginosa. J. Mol. Biol. 389(1), 134-145 (2009).
31. Opperman TJ, Nguyen ST. Recent advances toward a molecular mechanism of efflux pump inhibition. Front. Microbiol. 6, 421 (2015).
32. Prasad R, Goffeau A. Yeast ATP-binding cassette transporters conferring multidrug resistance. Annu. Rev. Microbiol. 66, 39-63 (2012).
33. Cannon RD, Holmes AR. Learning the ABC of oral fungal drug resistance. Mol. Oral. Microbiol. 30(6), 425-437 (2015).
34. Prasad R, Rawal MK, Shah AH. Candida efflux ATPases and antiporters in clinical drug resistance. Adv. Exp. Med. Biol. 892, 351-376 (2016).
35. Niimi K, Harding DR, Holmes AR et al. Specific interactions between the Candida albicans ABC transporter Cdr1p ectodomain and a d-octapeptide derivative inhibitor. Mol. Microbiol. 85(4), 747-767 (2012).
36. Maurya IK, Thota CK, Verma SD et al. Rationally designed transmembrane peptide mimics of the multidrug transporter protein Cdr1 act as antagonists to selectively block drug efflux and chemosensitize azole-resistant clinical isolates of Candida albicans. J. Biol. Chem. 288(23), 16775-16787 (2013).
37. Shah AH, Rawal MK, Dhamgaye S, Komath SS, Saxena AK, Prasad R. Mutational analysis of intracellular loops identify cross talk with nucleotide binding domains of yeast ABC transporter Cdr1p. Sci. Rep. 5, 11211 (2015).
38. Safa AR. Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators. Curr. Med. Chem. Anticancer Agents 4(1), 1-17 (2004).
39. Sa-Correia I, dos Santos SC, Teixeira MC, Cabrito TR, Mira NP. Drug:H+ antiporters in chemical stress response in yeast. Trends Microbiol. 17(1), 22-31 (2009).
40. Yin Y, He X, Szewczyk P, Nguyen T, Chang G. Structure of the multidrug transporter EmrD from Escherichia coli. Science 312(5774), 741-744 (2006).
41. Gbelska Y, Krijger JJ, Breunig KD. Evolution of gene families: the multidrug resistance transporter genes in five related yeast species. FEMS Yeast Res. 6(3), 345-355 (2006).
42. Janbon G, Ormerod KL, Paulet D et al. Analysis of the genome and transcriptome of Cryptococcus neoformans var. grubii reveals complex RNA expression and microevolution leading to virulence attenuation. PLoS Genet. 10(4), e1004261 (2014).
43. Costa C, Dias PJ, Sa-Correia I, Teixeira MC. MFS multidrug transporters in pathogenic fungi: do they have real clinical impact? Front. Physiol. 5, 197 (2014).
44. Maebashi K, Niimi M, Kudoh M et al. Mechanisms of fluconazole resistance in Candida albicans isolates from Japanese AIDS patients. J. Antimicrob. Chemother. 47(5), 527-536 (2001).
45. Sanglard D, Ischer F, Calabrese D, Majcherczyk PA, Bille J. The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob. Agents Chemother. 43(11), 2753-2765 (1999).
46. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39(11), 2378-2386 (1995).
47. White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41(7), 1482-1487 (1997).
48. White TC, Holleman S, Dy F, Mirels LF, Stevens DA. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob. Agents Chemother. 46(6), 1704-1713 (2002).
49. Youngsaye W, Hartland CL, Morgan BJ et al. ML212: a small-molecule probe for investigating fluconazole resistance mechanisms in Candida albicans. Beilstein J. Org. Chem. 9, 1501-1507 (2013).
50. De Hertogh B, Carvajal E, Talla E, Dujon B, Baret P, Goffeau A. Phylogenetic classification of transporters and other membrane proteins from Saccharomyces cerevisiae. Funct. Integr. Genomics 2(4-5), 154-170 (2002).
51. Decottignies A, Grant AM, Nichols JW, de Wet H, McIntosh DB, Goffeau A. ATPase and multidrug transport activities of the overexpressed yeast ABC protein Yor1p. J. Biol. Chem. 273(20), 12612-12622 (1998).
52. Niimi K, Harding DR, Parshot R et al. Chemosensitization of fluconazole resistance in Saccharomyces cerevisiae and pathogenic fungi by a d-octapeptide derivative. Antimicrob. Agents Chemother. 48(4), 1256-1271 (2004).
53. Diwischek F, Morschhauser J, Holzgrabe U. Cerulenin analogues as inhibitors of efflux pumps in drug-resistant Candida albicans. Arch. Pharm. (Weinheim) 342(3), 150-164 (2009).
54. Holmes AR, Keniya MV, Ivnitski-Steele I et al. The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates. Antimicrob. Agents Chemother. 56(3), 1508-1515 (2012).
55. Keniya MV, Fleischer E, Klinger A, Cannon RD, Monk BC. Inhibitors of the Candida albicans major facilitator superfamily transporter Mdr1p responsible for fluconazole resistance. PLoS ONE 10(5), e0126350 (2015).
56. Lamping E, Monk BC, Niimi K et al. Characterization of three classes of membrane proteins involved in fungal azole resistance by functional hyperexpression in Saccharomyces cerevisiae. Eukaryot. Cell 6(7), 1150-1165 (2007).
57. Maki N, Dey S. Biochemical and pharmacological properties of an allosteric modulator site of the human P-glycoprotein (ABCB1). Biochem. Pharmacol. 72(2), 145-155 (2006).
58. Nakamura K, Niimi M, Niimi K et al. Functional expression of Candida albicans drug efflux pump Cdr1p in a Saccharomyces cerevisiae strain deficient in membrane transporters. Antimicrob. Agents Chemother. 45(12), 3366-3374 (2001).
59. Shukla S, Saini P, Smriti, Jha S, Ambudkar SV, Prasad R. Functional characterization of Candida albicans ABC transporter Cdr1p. Eukaryot. Cell 2(6), 1361-1375 (2003).
60. Lacka I, Konieczny MT, Bulakowska A et al. Chemosensitization of multidrug resistant Candida albicans by the oxathiolone fused chalcone derivatives. Front. Microbiol. 6, 783 (2015).
61. Li XC, Jacob MR, Ding Y et al. Capisterones A and B, which enhance fluconazole activity in Saccharomyces cerevisiae, from the marine green alga Penicillus capitatus. J. Nat. Prod. 69(4), 542-546 (2006).
62. Schuetzer-Muehlbauer M, Willinger B, Egner R, Ecker G, Kuchler K. Reversal of antifungal resistance mediated by ABC efflux pumps from Candida albicans functionally expressed in yeast. Int. J. Antimicrob. Agents 22(3), 291-300 (2003).
63. Cannon R, Sklar LA, Lindsley C. Phenotypic HTS multiplex for anti-fungal efflux pump inhibitors. PubChem Bioassay Screening Summary; PubChem AID 485335 (2010). http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi
64. NIH Molecular Libraries Small Molecule Repository Home Page. https://mlsmr.evotec.com/MLSMR-HomePage/index.html
65. Prestwick Chemical Library. 220 Boulevard Gonthier d'Andernach Parc d'innnovation, 67400 ILLKIRCH, France. www.prestwickchemical.com/prestwick-chemical-library
66. Digirolamo JA, Li XC, Jacob MR, Clark AM, Ferreira D. Reversal of fluconazole resistance by sulfated sterols from the marine sponge Topsentia sp. J. Nat. Prod. 72(8), 1524-1528 (2009).
67. Hiraga K, Wanigasekera A, Sugi H, Hamanaka N, Oda K. A novel screening for inhibitors of a pleiotropic drug resistant pump, Pdr5, in Saccharomyces cerevisiae. Biosci. Biotechnol. Biochem. 65(7), 1589-1595 (2001).
68. Hiraga K, Yamamoto S, Fukuda H, Hamanaka N, Oda K. Enniatin has a new function as an inhibitor of Pdr5p, one of the ABC transporters in Saccharomyces cerevisiae. Biochem. Biophys. Res. Commun. 328(4), 1119-1125 (2005).
69. Lee MD, Galazzo JL, Staley AL et al. Microbial fermentation-derived inhibitors of efflux-pump-mediated drug resistance. Farmaco 56(1-2), 81-85 (2001).
70. Wanigasekera A, Hiraga K, Hamanaka N, Oda K. Purification and some properties of an inhibitor for a yeast pleiotropic drug resistant pump from Kitasatospora sp. E-420. Biosci. Biotechnol. Biochem. 65(10), 2353-2357 (2001).
71. Yamamoto S, Hiraga K, Abiko A, Hamanaka N, Oda K. A new function of isonitrile as an inhibitor of the Pdr5p multidrug ABC transporter in Saccharomyces cerevisiae. Biochem. Biophys. Res. Commun. 330(2), 622-628 (2005).
72. Lacka I, Konieczny MT, Bulakowska A, Rzymowski T, Milewski S. Antifungal action of the oxathiolone-fused chalcone derivative. Mycoses 54(5), e407-e414 (2011).
73. Kolaczkowski M, Kolaczkowska A, Motohashi N, Michalak K. New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters. Antimicrob. Agents Chemother. 53(4), 1516-1527 (2009).
74. Sharma M, Manoharlal R, Shukla S et al. Curcumin modulates efflux mediated by yeast ABC multidrug transporters and is synergistic with antifungals. Antimicrob. Agents Chemother. 53(8), 3256-3265 (2009).
75. Singh P, Kaur J, Yadav B, Komath SS. Design, synthesis and evaluations of acridone derivatives using Candida albicans-search for MDR modulators led to the identification of an anti-candidiasis agent. Bioorg. Med. Chem. 17(11), 3973-3979 (2009).
76. Ivnitski-Steele I, Holmes AR, Lamping E, Monk BC, Cannon RD, Sklar LA. Identification of Nile red as a fluorescent substrate of the Candida albicans ATPbinding cassette transporters Cdr1p and Cdr2p and the major facilitator superfamily transporter Mdr1p. Anal. Biochem. 394(1), 87-91 (2009).
77. Szczepaniak J, Lukaszewicz M, Krasowska A. Detection of inhibitors of Candida albicans Cdr transporters using a diS-C3(3) fluorescence. Front. Microbiol. 6, 176 (2015).
78. Campbell BC, Chan KL, Kim JH. Chemosensitization as a means to augment commercial antifungal agents. Front. Microbiol. 3, 79 (2012).
79. Hartland CL, Youngsaye W, Dockendorff C et al. Identification of small molecules that selectively inhibit fluconazole-resistant Candida albicans in the presence of fluconazole but not in its absence-Probe 3. In: Probe Reports from the NIH Molecular Libraries Program. Bethesda, MD (2010).
80. Hartland CL, Youngsaye W, Morgan B et al. Identification of small molecules that selectively inhibit fluconazole-resistant Candida albicans in the presence of fluconazole but not in its absence-Probe 2. In: Probe Reports from the NIH Molecular Libraries Program. MD, USA (2010).
81. Youngsaye W, Vincent B, Hartland CL et al. Piperazinyl quinolines as chemosensitizers to increase fluconazole susceptibility of Candida albicans clinical isolates. Bioorg. Med. Chem. Lett. 21(18), 5502-5505 (2011).
82. LaFleur MD, Lucumi E, Napper AD, Diamond SL, Lewis K. Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms. J. Antimicrob. Chemother. 66(4), 820-826 (2011).
83. Lafleur MD, Sun L, Lister I et al. Potentiation of azole antifungals by 2-adamantanamine. Antimicrob. Agents Chemother. 57(8), 3585-3592 (2013).
84. Tanabe K, Lamping E, Nagi M et al. Chimeras of Candida albicans Cdr1p and Cdr2p reveal features of pleiotropic drug resistance transporter structure and function. Mol. Microbiol. 82(2), 416-433 (2011).
85. Zhang L, Yan K, Zhang Y et al. High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections. Proc. Natl Acad. Sci. USA 104(11), 4606-4611 (2007).
86. Kolaczkowski M, Michalak K, Motohashi N. Phenothiazines as potent modulators of yeast multidrug resistance. Int. J. Antimicrob. Agents 22(3), 279-283 (2003).
87. Ricardo E, Costa-de-Oliveira S, Dias AS, Guerra J, Rodrigues AG, Pina-Vaz C. Ibuprofen reverts antifungal resistance on Candida albicans showing overexpression of CDR genes. FEMS Yeast Res. 9(4), 618-625 (2009).
88. Sharma M, Prasad R. The quorum-sensing molecule farnesol is a modulator of drug efflux mediated by ABC multidrug transporters and synergizes with drugs in Candida albicans. Antimicrob. Agents Chemother. 55(10), 4834-4843 (2011).
89. Tanabe K, Lamping E, Adachi K et al. Inhibition of fungal ABC transporters by unnarmicin A and unnarmicin C, novel cyclic peptides from marine bacterium. Biochem. Biophys. Res. Commun. 364(4), 990-995 (2007).
90. Limtrakul P, Anuchapreeda S, Buddhasukh D. Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. BMC Cancer 4, 13 (2004).
91. Schmid D, Ecker G, Kopp S, Hitzler M, Chiba P. Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements. Biochem. Pharmacol. 58(9), 1447-1456 (1999).
92. Liu XL, Tee HW, Go ML. Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein. Bioorg. Med. Chem. 16(1), 171-180 (2008).
93. Dornetshuber R, Heffeter P, Sulyok M et al. Interactions between ABC-transport proteins and the secondary Fusarium metabolites enniatin and beauvericin. Mol. Nutr. Food Res. 53(7), 904-920 (2009).
94. Suzuki K, Saito K, Tsujimura S et al. Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis. J. Rheumatol. 37(3), 512-520 (2010).
95. Hayama K, Ishibashi H, Ishijima SA et al. A d-octapeptide drug efflux pump inhibitor acts synergistically with azoles in a murine oral candidiasis infection model. FEMS Microbiol. Lett. 328(2), 130-137 (2012).
96. Sanglard D, Ischer F, Monod M, Bille J. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob. Agents Chemother. 40(10), 2300-2305 (1996).
97. Wirsching S, Moran GP, Sullivan DJ, Coleman DC, Morschhauser J. MDR1-mediated drug resistance in Candida dubliniensis. Antimicrob. Agents Chemother. 45(12), 3416-3421 (2001).
98. Vachova L, Stovicek V, Hlavacek O et al. Flo11p, drug efflux pumps, and the extracellular matrix cooperate to form biofilm yeast colonies. J. Cell Biol. 194(5), 679-687 (2011).
99. Gaskova D, Cadek R, Chaloupka R, Vacata V, Gebel J, Sigler K. Monitoring the kinetics and performance of yeast membrane ABC transporters by diS-C3(3) fluorescence. Int. J. Biochem. Cell Biol. 34(8), 931-937 (2002).
100. Edwards BS, Sklar LA. Flow cytometry: impact on early drug discovery. J. Biomol. Screen. 20(6), 689-707 (2015).
101. Tegos GP, Evangelisti AM, Strouse JJ, Ursu O, Bologa C, Sklar LA. A high throughput flow cytometric assay platform targeting transporter inhibition. Drug Discov. Today Technol. 12, e95-e103 (2014).
102. Young SM, Bologa C, Prossnitz ER, Oprea TI, Sklar LA, Edwards BS. High-throughput screening with HyperCyt flow cytometry to detect small molecule formylpeptide receptor ligands. J. Biomol. Screen. 10(4), 374-382 (2005).
103. Sandberg M, Maattanen A, Peltonen J, Vuorela PM, Fallarero A. Automating a 96-well microtitre plate model for Staphylococcus aureus biofilms: an approach to screening of natural antimicrobial compounds. Int. J. Antimicrob. Agents 32(3), 233-240 (2008).
104. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4(2), 67-73 (1999).
105. Goffeau A, Dufour JP. Plasma membrane ATPase from the yeast Saccharomyces cerevisiae. Methods Enzymol. 157, 528-533 (1988).
106. Silva LV, Sanguinetti M, Vandeputte P, Torelli R, Rochat B, Sanglard D. Milbemycins: more than efflux inhibitors for fungal pathogens. Antimicrob. Agents Chemother. 57(2), 873-86 (2013).